ILT, when it comes to pricing such products, developmental costs totaling into hundreds of millions, or more are far more important than the actual cost of making a product. Pills that cost pennies still have treatment costs into the hundreds of thousands and it's justified by developmental costs.
No doubt, manual manufacturing costs a few thousand more, but that's tiny when compared to developmental costs. I'd be willing to bet the price NICE agrees to pay won't change even a single dollar whether produced manually of with the EDEN. Remember, sales also have to cover developmental costs of the EDEN Unit, I would suspect that it goes into the tens of millions, or more.
Much the same is true of the equipment BP's have built to mass produce their products. A pill might cost pennies, perhaps IV packs cost more, but not that much. Still, even treatment with products that are generic aren't cheap, especially if they're being administered against deadly diseases where patients number into the hundreds of thousands, a tiny fraction of the world's population.
When you create something much of the world will take, like aspirin, much lower prices work well, and are very profitable. The cost of the pill for treating a cancer might be no more than that of aspirin, but the patient, or more properly their insurance will pay far more, even after the company making it has had their developmental costs repaid many times over, even if it's generic.
I suspect that once we're producing EDEN units in mass the first time they're used for treatment may return the cost of the mass produced unit. I believe that FlaskWorks will only lease them, and be responsible for monitoring each unit, maintaining it, and doing any update required. They will maintain control of every unit and disposable cassette.
Gary
Market Data 
Markets 
AI
